RE:RE:RE:CG OncologyCG’s lead asset is an oncolytic virus immunotherapy, recently granted an Accelerated Approval for the intravesical infusion treatment of high-grade non-muscle invasive bladder cancer (NMIBC).
With intravesical therapy, the doctor puts a liquid drug right into the patient's bladder rather than giving it by mouth or injecting it into their blood. The drug is given through a tube (urinary catheter) that's been put into the patient's bladder through their urethra.
CG Oncology's OV is an intravesically delivered oncolytic immunotherapy that was evaluated in BOND-003, a single-arm, Phase 3, monotherapy clinical trial for the treatment of patients with high-risk BCG-unresponsive NMIBC with carcinoma in situ with or without Ta/T1 disease.
https://pubmed.ncbi.nlm.nih.gov/37410243/
https://www.cancer.org/cancer/types/bladder-cancer/treating/intravesical-therapy.html
https://www.pharmexec.com/view/fda-grants-fast-track-breakthrough-designations-to-cg-oncology-inc-s-cretostimogene-grenadenorepvec